Nektar Therapeutics (NASDAQ:NKTR) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Nektar Therapeutics (NASDAQ:NKTR) have received an average rating of “Moderate Buy” from the seven research firms that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $4.08.

NKTR has been the topic of a number of research reports. B. Riley assumed coverage on shares of Nektar Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $4.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $6.50 price objective on shares of Nektar Therapeutics in a research note on Monday, January 13th. BTIG Research reaffirmed a “buy” rating and set a $4.00 target price on shares of Nektar Therapeutics in a report on Monday, September 30th. Finally, Piper Sandler initiated coverage on Nektar Therapeutics in a report on Monday, November 4th. They issued an “overweight” rating and a $7.00 price target for the company.

Nektar Therapeutics Stock Up 0.0 %

Nektar Therapeutics stock opened at $0.89 on Tuesday. The stock has a 50-day moving average price of $1.03 and a 200 day moving average price of $1.20. The company has a market capitalization of $164.54 million, a price-to-earnings ratio of -1.06 and a beta of 0.59. Nektar Therapeutics has a 52 week low of $0.48 and a 52 week high of $1.93.

Insider Buying and Selling at Nektar Therapeutics

In related news, insider Jonathan Zalevsky sold 51,115 shares of the firm’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $0.94, for a total value of $48,048.10. Following the transaction, the insider now directly owns 326,904 shares of the company’s stock, valued at approximately $307,289.76. This trade represents a 13.52 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Mark Andrew Wilson sold 33,402 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $0.90, for a total value of $30,061.80. Following the sale, the insider now owns 351,892 shares of the company’s stock, valued at approximately $316,702.80. This trade represents a 8.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 155,575 shares of company stock valued at $149,878. Company insiders own 3.71% of the company’s stock.

Institutional Trading of Nektar Therapeutics

Several large investors have recently made changes to their positions in NKTR. Victory Capital Management Inc. acquired a new stake in Nektar Therapeutics during the 2nd quarter worth $29,000. Valence8 US LP acquired a new position in Nektar Therapeutics during the third quarter worth about $34,000. Intech Investment Management LLC purchased a new stake in Nektar Therapeutics during the 3rd quarter valued at about $41,000. XTX Topco Ltd acquired a new stake in Nektar Therapeutics in the 3rd quarter valued at about $46,000. Finally, HB Wealth Management LLC lifted its stake in Nektar Therapeutics by 44.0% in the 4th quarter. HB Wealth Management LLC now owns 64,100 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 19,600 shares in the last quarter. 75.88% of the stock is currently owned by hedge funds and other institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.